RT Journal Article
SR Electronic
T1 Peripheral nerve induction of inhibitory brain circuits to treat Tourette syndrome: A randomized crossover trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.01.23285304
DO 10.1101/2023.02.01.23285304
A1 Iverson, Ann M.
A1 Arbuckle, Amanda L.
A1 Ueda, Keisuke
A1 Song, David Y.
A1 Bihun, Emily C.
A1 Koller, Jonathan M.
A1 Wallendorf, Michael
A1 Black, Kevin J.
YR 2023
UL http://medrxiv.org/content/early/2023/02/06/2023.02.01.23285304.abstract
AB A prior study showed that rhythmic, but not arrhythmic, 12 Hz stimulation of the median nerve (MNS) entrained sensorimotor cortex EEG signal, and found that 10 Hz MNS improved tics in Tourette syndrome (TS). However, no control condition was tested and stimulation blocks lasted only 1 minute. We set out to replicate the TS results and to test whether tic improvement occurs by the proposed cortical entrainment mechanism. Thirty-two people with TS, age 15-64, completed two study visits with repeated MNS on and off blocks in random order, one visit for rhythmic and one for arrhythmic MNS. Subjects and staff were blind to order; a video rater was additionally blind to stimulation and to order of visits and blocks. Rhythmic MNS at 10 Hz improved tics. Both rhythmic and arrhythmic 12 Hz MNS improved tic frequency, intensity and urges without significant difference. Participant masking was effective and there was no carryover effect. Several participants described dramatic benefit. Discomfort was minimal. MNS benefit did not persist after the end of stimulation. These results replicate the tic benefit from MNS, but show that the EEG entrainment hypothesis cannot explain that benefit. Another electrophysiological mechanism may explain benefit; alternatively, these data do not exclude a placebo effect.Registration ClinicalTrials.gov, NCT04731714.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04731714Clinical Protocols https://osf.io/v87qs Funding StatementSupported by the Washington University Institute of Clinical and Translational Sciences (NIH CTSA grant UL1TR002345) and by the Washington University Yearlong Research Program Dean's Fellowship (to author AMI). REDCap is additionally supported by the Siteman Comprehensive Cancer Center and NCI Cancer Center Support Grant P30CA091842.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Human Research Protection Office (IRB) of Washington University in St. Louis gave ethical approval for this work and deemed it a non-significant risk device study (approval # 202011092).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study will be published at https://osf.io/mtbzf/ when the article is published in a journal, with the exception of video recordings, which cannot feasibly be de-identified. https://osf.io/8jtep https://osf.io/mtbzf